Introduction Antibody-drug conjugates (ADCs) are “biological bullets” formed by conjugating cytotoxic drugs (payloads) to antibodies via a “linker.” They consist of five components: target, antibody, linker, payload, and conjugation method. Each part is crucial to the function of ADCs, but today we will focus on the linker that connects the antibody and payload, examining the … Read more
Since the first use of cytotoxic chemicals to treat cancer, oncologists have been searching for ways to enhance efficacy without significantly increasing overall toxicity to patients. One of the methods attempted to improve the killing effect on tumor cells is the use of cytotoxic agents with potency at picomolar or lower levels (such as microtubule … Read more
History of ADC Drug Development Phase 1 (1906-1982), the concept of targeted therapy was proposed, and the technology took shape. Phase 2 (1983-2011), transition from clinical trials to commercialization, Mylotarg® was approved for market. Phase 3 (2012-present), explosive growth of ADC products. The five key elements of ADC drugs are target, antibody, linker, cytotoxic agent, … Read more
The development of ADC drugs has not been smooth sailing, with nearly 100 years of history since the concept of the “magic bullet” was proposed, but ultimately, the clouds have parted to reveal the moon. DS8201 has redefined ADC, but it is not the end of ADC drugs, rather a new beginning. A comprehensive understanding … Read more
ADC Field Blooms, new technologies evolve like a rolling tide, propelling biomedicine into high-speed mode. This is the best of times. As early as the early 20th century, Paul Ehrlich first proposed the concept of “magic bullets”; however, the first ADC drug, Mylotarg® (gemtuzumab ozogamicin), was not approved until nearly a century later. Every cloud … Read more
1 Introduction Antibody-drug conjugates (ADC) are an emerging technology that selectively targets cancer cells to overcome the limitations of chemotherapy. ADC binds to antigens, especially those overexpressed on the surface of cancer cells, reducing side effects caused by nonspecific targeting and improving the therapeutic index. The ideal efficacy of an ADC is entirely dependent on … Read more
Since the first use of cytotoxic chemicals to treat cancer, oncologists have been searching for ways to improve efficacy without significantly increasing overall toxicity to patients. One of the methods attempted to enhance the killing effect on tumor cells is the use of cytotoxic agents with potency at picomolar or lower levels (such as microtubule … Read more
Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies (mAbs) with small molecule drugs through linkers. The specificity of mAbs for tumor cells allows small molecule drugs to act effectively within tumor tissues, significantly reducing the high toxicity and side effects of traditional small molecule drugs while improving overall therapeutic efficiency. Currently, there are 13 … Read more
Antibody-drug conjugates (ADCs) consist of linkers, payloads, and monoclonal antibodies (mAbs). They combine the advantages of high specificity targeting and potent cytotoxic effects, achieving precise and efficient elimination of cancer cells, making them a hot topic in cancer drug development. Since the first ADC drug Mylotarg® was approved by the FDA in 2000, as of … Read more
<span>esp8266</span> is primarily used for IoT development and can work with various sensors to meet our needs. In this article, let’s explore the world of <span>esp8266</span> together! ESP8266 Development Routes Route One: DIY Approach You need to write the relevant sensor code yourself and solve various dependency issues. You need to purchase a public network … Read more